Merck products by revenue. in a research report issued on Thursday, November 20th.

Merck products by revenue -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2024. (2) Alliance Revenue represents Merck’s share of profits, which are product sales Nov 14, 2024 · Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite recent volatility. That’s why the pharma giant Mar 31, 2024 · Animal Health Revenue refers to the total revenue generated by Merck Animal Health from the sale of products and services related to animal health care. Jul 29, 2021 · Pharmaceutical Revenue Second-quarter pharmaceutical sales increased 22% to $10. Davis, chairman and chief executive officer, Merck. Feb 4, 2025 · Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2024. 7% to € 2,777 million (2023: € 2,824 million) and resulted in a reduction in earnings per share to € 6. Inc. Jul 29, 2025 · Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1. This growth was, according to Merck CFO Caroline Litchfield, driven by oncology product sales, as well as animal health and new product Jul 29, 2025 · Merck & Co. […] Feb 4, 2025 · Merck’s latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant. Oct 31, 2024 · The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. Apr 24, 2025 · Discover Merck's Q1 2025 performance: $15. We aspire to be the premier research-intensive biopharmaceutical company 3 days ago · Merck and Elevance Health stocks are top dividend growth picks with solid yields and attractive valuations. "Our company made strong progress to start the year, with increasing Jun 9, 2025 · A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA approval, introducing competition to products already available from Pfizer and Sanofi. How does Merck diversify its revenue streams? Merck diversifies its revenue streams through a wide range of products in both human health (pharmaceuticals and vaccines) and animal health sectors, reducing dependency on any single product. Six of the top 20 drugmakers had double-digit increases in 2024, compared to just two in 2023. 9% growth over 2023. Our company announced Q1 worldwide sales of $15. 49). 01. J. Merck revenue for the quarter ending March 31, 2025 was $5. 01 billion in revenue for the full year. The COVID-19 pandemic unfavorably affected sales in the second quarter of 2021 but to a lesser extent than in the second quarter of 2020. “Our business is demonstrating strong momentum as we exit the first half of the year,” said Rob Davis, chairman and chief executive officer. 1 billion, an increase of 7% from Q2 2023. Merck. Dec 31, 2024 · Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. Pharmaceutical sales growth in the first quarter was 18% excluding LAGEVRIO sales and was primarily driven by oncology, vaccines and hospital acute care products. 168B, a 6. , Rahway, N. 1 day ago · Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Merck is the world's premier research-intensive biopharmaceutical company. COVID-19-related disruptions negatively affected sales in the fourth quarter of 2020, which benefited year-over-year sales growth. 78 per share for Jul 28, 2022 · Pharmaceutical Revenue Second-quarter pharmaceutical sales increased 28% to $12. The net income attributable to Merck KGaA shareholders declined by -1. Non-GAAP EPS was $1. Apr 2, 2025 · The statistic depicts the revenue of pharmaceutical and chemical company Merck KGaA (EMD) from 2014 to 2024, distributed by segment. View the list of products marketed in the U. Oct 26, 2023 · RAHWAY, N. 0 billion reflecting sales of molnupiravir and growth in oncology, vaccines and hospital acute care products. View MRK financial statements in full, including balance sheets and ratios. ’s Keytruda is the world’s best-selling drug and has been a cancer juggernaut for more than a decade, scoring its 40th indication in June and adding yet another in late September. On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against cancer-causing HPV in China, which previously powered Merck’s growth. Oct 25, 2024 · Despite a strong Q2, Merck's stock fell due to concerns over Gardasil and Winrevair. 3 billion in 2022. 5 billion, excluding the unfavorable effect from foreign exchange, sales grew 8%. Jul 29, 2025 · Merck’s (NYSE: MRK) Q2 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. 9 billion, including a positive Oct 26, 2023 · Merck's COVID-19 antiviral treatment Lagevrio racked up sales of $640 million in Q3, shocking analysts who figured it would generate $120 million. Animal Health revenue is derived from livestock and companion animal products. (MRK). Mar 7, 2024 · Accounting and measurement policies Segment reporting The Merck Group’s business activities are broken down into the three operational business sectors of Life Science, Healthcare, and Electronics, as well as the central Group functions. Apr 24, 2025 · Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. 5 billion and year-on-year growth of 17. “2023 was another very strong year for Merck. Pharmaceutical sales growth in the second quarter was 16% excluding LAGEVRIO sales, and was primarily driven by oncology, vaccines and hospital acute care products. Zacks Research analyst Team now anticipates that the company will earn $2. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. Mar 6, 2025 · The tax rate in fiscal 2023 was lower due to a non-recurring tax effect in the form of deferred tax income. statistics reveal that the company recorded higher revenues in 2023, with the figure standing at approximately $60. ” Sources Merck to Acquire Cidara Therapeutics, Inc. Our company announced Q2 worldwide sales of $15. ’s total revenue was generated from the company’s domestic market in the United States. annual income statement. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. “Merck has begun 2024 with continuing momentum in our business. , Inc. (2) Alliance Revenue represents Merck’s share of profits, which are product sales Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. Jul 29, 2025 · RAHWAY, N. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. See for yourself in our detailed reports and financials. 17 billion in total sales, up 7 percent from $60. Merck KGaA, Darmstadt, Germany, keeps growing profitably. “Through excellent scientific, commercial and operational execution Feb 2, 2023 · RAHWAY, N. Feb 20, 2025 · Merck is a company with a strong position in the healthcare sector, with innovative product lines such as the cancer drug Keytruda being a pillar of its earnings. Davis, chairman and chief executive officer. Keytruda is a biotech-derived cancer drug. 2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral portfolio with a Phase III drug Jun 20, 2025 · Explore Merck's latest developments: Keytruda's expanded FDA approval, promising oncology and vaccine pipeline, and strategic moves to counter patent cliffs. 78 per share for Feb 4, 2025 · Full-year financials In 2024, Merck brought in $64. Oct 28, 2021 · Financial Outlook Merck continues to experience strong global underlying demand across its business. Its non-GAAP profit of $2. 6 billion, an increase of 7% from Q4 2023. Jun 20, 2025 · Revenues lifted by sales of cancer treatments The majority of Merck’s revenue comes from its pharmaceutical segment, which includes human health and vaccine products. However, the pharmaceutical landscape is shifting rapidly. Other revenues are primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements. Jul 11, 2025 · While Merck has built a solid pipeline and commenced new product launches, the timeline remains tight and the revenue gap significant. 72% increase from 2021. 5 billion). Pharmaceutical revenue is primarily driven by sales of key products like KEYTRUDA, GARDASIL, and WINREVAIR, across various therapeutic areas including oncology, vaccines, and cardiovascular. As such, Keytruda accounted for about 42% of the company’s sales in 2023, which is a lot of weight to bear for a tentpole drug teetering on the edge of a patent cliff. GAAP and non-GAAP EPS in the fourth quarter of 2024 include a charge of $0. The Life Science business sector encompasses business with tools . Pharmaceutical Revenue Fourth-quarter pharmaceutical sales increased 7% to $10. 88 percent (US$ 4. , USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U. Mar 11, 2024 · 8. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2023. Davis, chairman and chief Oct 31, 2024 · RAHWAY, N. Across our Life Science business sector, we collaborate with the global scientific community to deliver innovations. 400 billion, also reflecting a 7% growth. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries. Nov 16, 2025 · Merck & Co. Our company announced worldwide sales of $16. We are harnessing the power of innovation to advance our deep pipeline and are maximizing […] Nov 13, 2025 · Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM ESTCompany ParticipantsFlorian Schraeder - Head of Investor RelationsBelén Garijo We would like to show you a description here but the site won’t allow us. 562B Apr 28, 2022 · Pharmaceutical Revenue First-quarter pharmaceutical sales increased 53% to $14. llaneous corporate revenues, including revenue hedging activities, as well as revenue Jun 20, 2025 · In 2024, half of Merck & Co. annual, quarterly & TTM sales, analyze it on an interactive chart, and compare its performance with other metrics Mar 6, 2025 · Life Science We are a leading global provider of products, solutions and services for a wide range of customers, including research and diagnostic labs, biotech and pharmaceutical companies, as well as the industrial sector. Jun 2, 2025 · Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. Feb 4, 2025 · RAHWAY, N. 65 for the full year of 2024. Sales in billion USD. The pharmaceutical segment alone generated $57. 13, which beat the Zacks Consensus Estimate of $2. The group includes around 250 companies; the main company is Merck KGaA in Germany. Jun 20, 2025 · Merck & Co. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022. Read more here. The Jun 20, 2025 · single share of its pharmaceutical revenue in 2024. Merck annual revenue for 2024 was $64. reported its second-quarter 2025 financial outcomes, revealing a nuanced performance where flagship oncology product KEYTRUDA drove substantial revenue gains amidst a slight decline in total sales. The company is Mar 26, 2025 · >40% of Merck & Co. Revenues boosted by sales of cancer treatments Merck & Co. 938 billion, a decline of 41%. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $64. [1] Oct 31, 2024 · Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 48 for the fourth quarter and $6. Feb 4, 2021 · Fourth-Quarter and Full-Year Revenue Performance The following table reflects sales of the company’s top pharmaceutical products, as well as sales of animal health products. The Jan 14, 2025 · Merck & Co. The company is Jul 29, 2025 · Merck MRK reported second-quarter 2025 adjusted earnings per share (EPS) of $2. Feb 4, 2025 · Merck's two big revenue products are its HPV vaccine, Gardasil, and cancer drug Keytruda. Feb 4, 2025 · Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. The COVID-19 pandemic unfavorably affected sales in the first quarter of 2021 by approximately $500 million, which favorably impacted the Feb 5, 2020 · Fourth-Quarter and Full-Year Revenue Performance The following table reflects sales of the company’s top pharmaceutical products, as well as sales of animal health products. […] Dec 30, 2024 · Get all-time historical data of Merck & Co. Jul 29, 2025 · Summary Merck's latest earnings present a nuanced picture of a pharmaceutical giant actively reshaping its future amidst contrasting product performances. 168 billion, marking a 7% increase year-on-year. . In 2024, 46 Mar 20, 2025 · Merck also continues to bring products to the market that contribute to its diverse revenue stream—for example, its cancer drug Bavencio and other emerging pipeline candidates—although these are not consistently listed among the absolute top sellers. Keytruda will generate $25 billion in sales for Merck this year. Jul 2, 2025 · Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new Jul 30, 2024 · Merck’s (NYSE: MRK) Q2 2024 results demonstrate strong business momentum and further progress in our diverse pipeline. Molnupiravir sales were $952 million in the fourth quarter of 2021 Feb 4, 2025 · Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $1. Feb 4, 2025 · Sum of quarterly amounts may not equal year-to-date amounts due to rounding. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2024. Merck revenue report 2025. 6 billion. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients Feb 3, 2022 · Pharmaceutical Revenue Fourth-quarter pharmaceutical sales increased 23% to $12. All three business sectors achieved organic increases in sales and earnings. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2023. 5 days ago · Investor relations Our science-led strategy is key to delivering long-term value for patients, employees and shareholders. 115B, a 1. Includes revenue by product/segment and other key performance indicators. This growth was, according to Merck CFO Caroline Litchfield, driven by oncology product sales, as well as animal health and new product Mar 16, 2024 · This concentration of revenue in a few products exposes Merck to the risk of potential revenue decline if it fails to successfully develop and launch new drugs to replace or diversify its product portfolio. 5 bn in sales, as Novo’s semaglutide nips at its heels Moving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29. “Our strong results this quarter reflect our talented team’s commitment to bringing forward important innovation and pursuing breakthroughs for all those who count on us,” said Robert M. Nov 10, 2025 · Current and historical revenue information for Merck & Co. While the oncology powerhouse KEYTRUDA continued its impressive trajectory, a significant revenue headwind emerged from a core vaccine franchise. Merck on Thursday reported fourth-quarter earnings and sales that beat analyst expectations, powered by strong growth in cancer and vaccine products. -- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter of 2024. Earnings, however, declined 7% year over year on a reported RAHWAY, N. 8 billion at the midpoint. 5 billion in sales, posting solid 17. *Alliance revenue for these products represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. Feb 5, 2025 · Merck generates revenue from Pharmaceuticals and Animal Health. "2022 was an exceptional year for Merck, which is a testament to the profound impact our medicines and vaccines are having on patients globally," said Robert M. Today we are looking at Merck (NYSE:MRK) and the best and Feb 5, 2025 · On February 4, Merck & Co. Merck & Co. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Feb 4, 2025 · Full-year sales growth was primarily driven by higher pricing across both the Companion Animal and Livestock product portfolios, and higher demand for poultry and swine products, as well as sales related to the acquisition of the Elanco aqua business. List of largest selling pharmaceutical products Best selling pharmaceuticals of U. 39 (2023: € 6. Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. has agreed to acquire Cidara Therapeutics for approximately $9. Jul 2, 2025 · This presentation of Merck & Co. Ten years of annual and quarterly financial statements and annual report data for Merck (MRK). Merck annual revenue for 2023 was $60. Merck was founded in Mar 26, 2025 · >40% of Merck & Co. After a strong fourth quarter, the company is looking toward 2025 with confidence. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. The company provides products in the areas of oncology, infectious diseases, cardio-metabolic disorders, immunology, neuroscience, and ophthalmology. 1 billion to $65. 4% increase from 2022. Today we are looking at Merck (NYSE:MRK) and the best and worst performers in the branded pharmaceuticals industry. The latter is facing patent expiry in 2028. In 2021, it raked in over $48 billion in revenues. (2) Alliance Revenue represents Merck’s share of profits, which are product sales Oct 31, 2024 · Sum of quarterly amounts may not equal year-to-date amounts due to rounding. -- (BUSINESS WIRE)-- Merck & Co. Products, Technology and Solutions Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the most innovative portfolios of veterinary medicines, vaccines and health management solutions and services, as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Apr 25, 2024 · RAHWAY, N. Our company announced Q4 worldwide sales of $15. Compare that to 2023, when eight of the top 20 drugmakers experienced revenue declines. 14 hours ago · Merck & Co. ”Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example […] At Merck, we're following the science to tackle some of the world's greatest health threats. 74 for the full year of 2024. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. market The top 5 best selling pharmaceuticals 2015–2019. As a result, Merck is narrowing the range of its full-year sales outlook. “In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches,” said Rob […] Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. Total Vaccines sales were $1,809 million in the first quarter of 2021 and $2,155 million in the first quarter of 2020. Aug 1, 2023 · RAHWAY, N. -- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2023. 12 billion in 2023 and inching over analysts' expectations of $64. 74% increase from 2023. 4 billion and $47. “Our business is demonstrating strong momentum as we exit the first half of the year,” said Robert M. 3 billion. But its patent is about to expire, leaving Merck with a gaping hole to fill—and a stock price that could be at risk. View MRK revenue history (year & quarter) and revenue breakdown by product or geography (region/country). 1 billion. Jul 29, 2025 · The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda. Feb 1, 2024 · RAHWAY, N. 1 billion, rising from $59. 5B revenue, strong oncology growth, challenges in China vaccines, and $9B manufacturing investment plans. Merck annual revenue for 2022 was $59. Discover its function, wide-ranging applications, and future. 13 per share was 5% above analysts’ consensus estimates. Nov 9, 2024 · With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. People who say the company’s products injured them have filed thousands of lawsuits against Merck. is a global healthcare company that generated over ** Aug 1, 2023 · RAHWAY, N. However, research and development (R&D) spending dropped significantly to $17. Feb 3, 2022 · Fourth-Quarter and Full-Year Revenue Performance The following table reflects sales of the company’s top pharmaceutical products, as well as sales of Animal Health products. Merck is the world's premier research-intensive, purpose-driven biopharmaceutical company. See more on MRK stock and its diversified pipeline of new drugs. Consequently, Merck is raising and narrowing its full-year estimated ranges for revenue and EPS. Feb 1, 2024 · With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. “Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Robert M. But with all its successes, Merck has had its share of controversy and legal troubles as well. Jul 16, 2025 · Merck is one of the largest pharmaceutical companies in the world. Shares of Merck Nov 14, 2025 · We are excited to be collaborating with Merck to realize the full value of this high priority product and contribute to our partner’s revenue growth by leveraging our scale capital and expertise. Oct 29, 2024 · Merck is a biopharmaceutical company that develops medicines and vaccines. Aug 1, 2024 · From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. There can Aug 1, 2023 · Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil Apr 25, 2024 · Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Oct 31, 2024 · Merck continues to experience strong growth, including from KEYTRUDA, new product launches and Animal Health. 72 for the fourth quarter and $7. Between 2022 and Apr 4, 2025 · In 2024, Merck’s Keytruda continued its reign with nearly $29. in a research report issued on Thursday, November 20th. 8 billion. 5 billion. , Diversifying Its Portfolio to Include Late-Phase Antiviral Agent. I am extremely pleased by the progress we’ve made to develop and deliver transformative therapies and vaccines that will help save and improve lives around the Apr 24, 2025 · RAHWAY, N. 9% year on year to $15. 's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. Explore Merck's investor events and presentations. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond," said Robert M. At mid-October 2021 exchange ranges, Merck now expects sales growth of 14% to 15% in 2021, with full-year 2021 revenue estimated to be between $47. 23 per share related to the execution of licensing agreements with LaNova Mar 7, 2024 · Fiscal 2023: Proven Resilience During Transitional Year Merck demonstrated the robustness of its diversified business model in a challenging market environment. Revenue Sources Jun 20, 2025 · Zoetis revenue share by animal type and country 2024 Zoetis revenue distribution in 2024, by product category Pharmaceutical revenue of Merck & Co by therapy class 2024 Get the detailed quarterly/annual income statement for Merck & Co. "Our pipeline is advancing and expanding, demonstrating Jul 30, 2024 · RAHWAY, N. , USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of Dec 31, 2021 · Business metrics and revenue breakdowns for Merck KGaA (MKKGY). While the company delivered strong overall growth in 2024, it faced unexpected headwinds in Oct 27, 2022 · Merck was recognized on Fortune’s 2022 Change the World list for its work to make HPV vaccines broadly available in underserved countries through partnerships and manufacturing investments. The company is ranked fourth on the list of largest biomedical companies by revenue. Apr 24, 2025 · Merck’s Keytruda retains throne with US$ 29. This segment structure reflects the internal organizational and reporting structure. Davis, chairman and Dec 31, 2024 · At MSD, known as Merck & Co. In reporting its second quarter 2025 financial results on Tuesday, the Rahway, New Jersey-based drug giant announced it is launching a $3 billion cost-cutting plan that includes layoffs and Jul 2, 2025 · This presentation of Merck & Co. Five others saw a revenue bump of Apr 24, 2025 · Merck’s (NYSE: MRK) Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. “Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis Oct 31, 2024 · Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Is now the time to buy The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. S. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. There can Aug 1, 2023 · Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil Jul 29, 2025 · NEW YORK – Merck is feeling the pressure of future Keytruda (pembrolizumab) patent losses years in advance. It offers pharmaceutical and animal health products in the forms of chewable and film-coated tablets, oral pellets and suspensions, and injections. dollars. Looking ahead, the branded pharmaceutical industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI Mar 6, 2025 · Merck returned to profitable growth in 2024 and delivered on its guidance for the year. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Feb 4, 2025 · Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64. Davis, chairman and chief executive /news/home/20250424880466/en/Merck-Announces-First-Quarter-2025-Financial-Results Jun 22, 2025 · With only one of the biopharma industry’s top 20 revenue companies seeing a year-over-year decline in sales, 2024 was a remarkable year of revenue growth for the industry. The Healthcare business sector discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis (MS Mar 6, 2025 · Merck returned to profitable growth in 2024 and delivered on its guidance for the year. Jun 25, 2025 · Merck & Co. 14 hours ago · Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Private Securities Litigation Reform Act of 1995. ’s best-selling drug in 2024 was once again Keytruda, generating nearly 30 billion U. Our company announced Q3 worldwide sales of $17. "Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example of acting decisively when science and Merck & Co. 81 billion. Data-driven analysis. Oct 30, 2025 · Merck’s (NYSE: MRK) Q3 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Feb 4, 2025 · Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and Jun 30, 2023 · In Healthcare, we operate as a global specialty innovator in the Neurology & Immunology and Oncology franchises as well as in the therapeutic areas of fertility and cardiovascular, metabolic and endocrinological disorders. Income statements, balance sheets, cash flow statements and key ratios. “ We delivered strong 4 days ago · Learn why Keytruda, a revolutionary cancer immunotherapy, is what is Merck's flagship product and its biggest revenue generator. (1) Only select products are shown. Only select products are shown. Keytruda's sales are expected to reach $30 billion this year. "We continue to make great progress as we advance our broad and deep pipeline, raise the bar of innovation, and bring forward leading-edge science to save and improve lives around the world," said Robert M. , Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. 8 billion, an increase of 9% from Q1 2023. , USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2025. 7 billion, an increase of 4% from Q3 2023. The pharmaceutical giant's remarkable performance Explore our quarterly reports, annual reports & proxy. This includes revenue from various products such as vaccines, pharmaceuticals, and other animal health products, as well as revenue from services like diagnostics and veterinary consulting. 283B, a 21. Excluding the favorable effect of foreign exchange, sales grew by 18%, reflecting ongoing recovery from the COVID-19 pandemic and strong underlying demand. (NYSE:MRK - Free Report) - Research analysts at Zacks Research lifted their Q3 2027 earnings estimates for shares of Merck & Co. Find out the revenue, expenses and profit or loss over the last fiscal year. Get a glimpse of how we work to improve lives. (MRK) stock, including a chart and comparison to related stocks. “I am Jul 29, 2025 · The multiyear effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda. The company’s outlook for the full 5 days ago · Investor relations Our science-led strategy is key to delivering long-term value for patients, employees and shareholders. 0 billion. The excellent performance of our business shows that we are on the right track. The COVID-19 pandemic unfavorably affected sales in the second quarter of 2021 by approximately $400 million, which favorably impacted the Feb 4, 2025 · Full-year financials In 2024, Merck brought in $64. Third-quarter revenue performance The following table reflects sales of the company’s top pharmaceutical products, as well as sales of Animal Health Jul 29, 2025 · Merck outlines $3B reinvestment initiative and expects 1%–2% revenue growth for 2025 while advancing new product launches Nov 14, 2024 · Merck accelerated its growth in the third quarter of 2024. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. Click here to learn more about MRK and ELV. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. The biopharmaceutical giant continues to navigate market challenges while strategically investing in growth areas. announced its 2024 financial results, revealing total revenue of $64. We aspire to be the premier research-intensive biopharmaceutical company Merck annual/quarterly revenue history and growth rate from 2010 to 2025. aaz igxxa qnr otdhyucl gqth yjh uhscw vosb uzri rxgzt dwuq qwqciio oivjm caph hvpfkf